CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- PositionGross margin is 17.4%, lower than 95% of its Diagnostics & Research peers (median 51.1%)
- FinancialsAltman Z-Score 9.18: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.99BCNY741.71M · vs all stocks (USD)
Revenue (TTM)
656.38MCNY97.61M · vs all stocks (USD)
Profit Margin
-5.47%vs Diagnostics & Research peers
Beta
-0.1740xvs all stocks
52-Week Change
74.27%vs all stocks
Market Capitalization
4.99BCNY741.71M · vs all stocks (USD)
Enterprise Value
4.70BCNY699.23M · vs all stocks (USD)
Price to Sales (TTM)
7.67xvs Diagnostics & Research peers
Price to Book (MRQ)
4.82xvs Diagnostics & Research peers
Enterprise to Revenue
7.16xvs Diagnostics & Research peers
Enterprise to EBITDA
-135.46xvs Diagnostics & Research peers
Gross Margin
17.40%vs Diagnostics & Research peers
Profit Margin
-5.47%vs Diagnostics & Research peers
Operating Margin
-5.23%vs Diagnostics & Research peers
Return on Assets (TTM)
-1.78%vs Diagnostics & Research peers
Return on Equity (TTM)
-3.23%vs Diagnostics & Research peers
Revenue (TTM)
656.38MCNY97.61M · vs all stocks (USD)
Revenue per Share (TTM)
1.46CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-12.20%vs Diagnostics & Research peers
Gross Profit (TTM)
92.25MCNY13.72M · vs all stocks (USD)
EBITDA (TTM)
-34.71MCNY-5.16M · vs all stocks (USD)
Net Income (TTM)
-35.93MCNY-5.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-32.36%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
-77.61MCNY-11.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
21.99MCNY3.27M · vs all stocks (USD)
Payout Ratio
0.00%vs Diagnostics & Research peers
Minority Interest (Equity)
1.74MCNYFY2025 · Dec 31, 2025Revenue
677.79MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
577.78MCNYFY2025 · Dec 31, 2025Gross Profit
100.01MCNYFY2025 · Dec 31, 2025Operating Income
-23.53MCNY-3.50M · vs all stocks (USD)
Pre-tax Income
-40.12MCNYFY2025 · Dec 31, 2025Income Tax Expense
-6.43MCNYFY2025 · Dec 31, 2025Net Income
-33.69MCNYFY2025 · Dec 31, 2025EBIT
-37.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-10.15MCNYFY2025 · Dec 31, 2025Research & Development
3.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
39.87MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.66MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.32MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-33.69MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
44.76KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-29.60MCNYFY2025 · Dec 31, 2025Free Cash Flow
-43.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
86.40MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-33.69MCNYFY2025 · Dec 31, 2025Other Non-cash Items
17.29MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.20MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.41MCNYFY2025 · Dec 31, 2025Capital Expenditures
-14.04MCNYFY2025 · Dec 31, 2025Purchase of Investments
-286.63MCNYFY2025 · Dec 31, 2025Sale of Investments
158.26MCNYFY2025 · Dec 31, 2025Other Investing Activity
1.26MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-141.16MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
126.97MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-114.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-52.66MCNYFY2025 · Dec 31, 2025Other Financing Charges
6.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-34.28MCNYFY2025 · Dec 31, 2025Shares Outstanding
398.05MSharesUpdated Aug 21, 2026Float Shares
172.39MSharesUpdated Aug 21, 2026% Held by Insiders
54.20%vs all stocks
% Held by Institutions
1.02%vs all stocks
Total Cash (MRQ)
115.58MCNY17.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2900CNYUpdated Aug 21, 2026Total Debt (MRQ)
94.63MCNY14.07M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0905xvs Diagnostics & Research peers
Current Ratio (MRQ)
3.05xvs Diagnostics & Research peers
Book Value per Share (MRQ)
2.62CNYUpdated Aug 21, 2026Total Assets
1.43BCNY212.44M · vs all stocks (USD)
Total Current Assets
1.12BCNYFY2025 · Dec 31, 2025Total Liabilities
368.90MCNYFY2025 · Dec 31, 2025Total Non-current Assets
304.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.02MCNYFY2025 · Dec 31, 2025Total Current Liabilities
366.88MCNYFY2025 · Dec 31, 2025Cash
96.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
10.07MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
106.47MCNYFY2025 · Dec 31, 2025Accounts Receivable
690.03MCNYFY2025 · Dec 31, 2025Inventory
172.64MCNYFY2025 · Dec 31, 2025Accounts Payable
266.40MCNYFY2025 · Dec 31, 2025Short-term Debt
59.26MCNYFY2025 · Dec 31, 2025Other Current Liabilities
361.94KCNYFY2025 · Dec 31, 2025Long-term Debt
2.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
398.05MCNYFY2025 · Dec 31, 2025Retained Earnings
43.93MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.06BCNY157.58M · vs all stocks (USD)
52-Week Low
6.12CNYUpdated Aug 21, 202652-Week High
31.22CNYUpdated Aug 21, 202652-Week Change
74.27%vs all stocks
Beta
-0.1740xvs all stocks
50-Day MA
11.27CNYUpdated Aug 21, 2026200-Day MA
16.86CNYUpdated Aug 21, 2026Avg 10-Day Volume
38.08MSharesUpdated Aug 21, 2026Avg 30-Day Volume
25.29MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0800CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 17.4%, lower than 95% of its Diagnostics & Research peers (median 51.1%)Significant
Gross margin: 0.17Industry median: 0.51Industry P5: 0.22Peers compared: 31.00
Financial Health
Altman Z-Score 9.18: safe zoneNotable
Altman Z-Score: 9.18
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Winstek Semiconductor Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Foshan Blue Rocket Electronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Jinxi Axle Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionRule
Jk Paper Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Beijing Navigation Control Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Jiangsu Olive Sensors High-Tech Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Cybrid Technologies Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Zhejiang Zhaofeng Mechanic Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
WuXi DeLinHai Environmental Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Queclink Wireless Solutions Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Tellgen Corporation
2 interpretationsPartial Recovery After Sharp DeclineDown-Close Share With Multi-Year Earnings Decrease
Guangdong Tecsun Science & Technology Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDown-Close Share With Multi-Year Earnings Decrease
Aekyung Chemical Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDown-Close Share With Multi-Year Earnings Decrease